← Back to Knowledge Base

Primary topic: TM6SF2 gene cholesterol and blood-fat handling

TM6SF2 Gene and Metabolism: What It Can Mean in a Pathway Report

TM6SF2 is tracked because it connects to lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling. The current evidence index links this gene to Lipids with 1 SNP and 1 curated claim.

What is the TM6SF2 gene?

Endoplasmic-reticulum/Golgi-associated regulator of hepatic lipid handling and VLDL secretion.

How TM6SF2 affects metabolism

When TM6SF2-related function is shifted, the practical effect is interpreted through lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling. This does not mean the pathway is active or impaired right now; it means the gene can help prioritize what to check next.

What happens when TM6SF2 is altered

Altered TM6SF2 signal should be treated as a DNA-based tendency, not a diagnosis. 1 claim currently passes the report-use gate. The useful question is whether symptoms, labs, and lifestyle context line up with the pathway signal.

Curated SNP evidence for TM6SF2

These SNPs come from the approved study-level evidence model. Each claim is scored from curated study rows, then gated before it can influence pathway scoring.

Evidence-backed report connection

TM6SF2 currently has 1 curated SNPs, 1 claim-level scores, and 1 claims eligible for pathway scoring.

Open the sample report
rs58542926TM6SF2 E167K1 claims · 2 study rows

biomarker tendency · T

hepatic VLDL secretion tendency

Strong

rs58542926 T / TM6SF2 E167K is associated with lower hepatic VLDL secretion tendency.

TM6SF2 rs58542926 T is staged as a reduced-function hepatic lipoprotein secretion allele.

Likely effectLower biomarker tendency
Signal sizeModerate signal
Evidence supportStrong support
Report useIncluded in pathway scoring
Show study evidence

Common symptoms people report

  • unexpected cholesterol or triglyceride results
  • family context around lipid markers
  • unclear ApoB, LDL-C, HDL-C, or triglyceride patterns

Biomarkers to validate

ApoB

Shows the number of atherogenic particles more directly than total cholesterol.

LDL-C, HDL-C, and triglycerides

Gives the basic lipid pattern that DNA can help contextualize.

Lp(a) or liver enzymes when relevant

Adds context for inherited lipid risk or liver lipid handling.

Where DNA analysis helps

DNA helps decide whether TM6SF2 deserves attention inside the broader Lipids pathway. It is most useful when combined with biomarkers instead of used as a standalone answer.

Example interpretation

TM6SF2 may add context to lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling, especially when its SNP evidence lines up with other genes in the same pathway.

Suggested validation: ApoB.

What to do next

  • Review the Lipids pathway result before interpreting TM6SF2 on its own.
  • Use relevant biomarkers to confirm whether this DNA tendency is visible in current biology.
  • Treat supplement or nutrition decisions as follow-up steps only after the pattern fits symptoms or labs.

Upload your DNA file and receive a structured metabolic pathway analysis with prioritized insights and suggested validation markers.

Get My DNA Report

Related pages